2026-04-29T04:10:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/255662025-12-18T13:00:43Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19616

00925njm 22002777a 4500 dc García-Rodriguez, Patricia author Hidalgo, Laura author Rodriguez-Milla, Miguel A author Somovilla-Crespo, Beatriz author Garcia-Castro, Javier author 2024 LIN28, a highly conserved RNA-binding protein that acts as a posttranscriptional modulator, plays a vital role in the regulation of T-cell development, reprogramming, and immune activity in infectious diseases and T-cell-based immunotherapies. LIN28 inhibit the expression of miRNAs, the most prevalent family of miRNAs in lymphocytes. Recently it has been suggested that enhances murine anti-tumor immune responses. Here, we investigated the impact of LIN28 upregulation on human T cell functions, focusing on its influence on CAR T cell therapy. LIN28 lentiviral transduction of human T cells led to a stable expression of LIN28 that significantly downregulated the miRNA family without affecting cell viability or expansion potential. LIN28 overexpression maintained human T cell phenotype markers and functionality but impaired the antitumoral cytotoxicity of NKG2D-CAR T cells both and . These findings highlight the intricate relationship between LIN28/ axis and human T cell functionality, including in CAR T cell therapy. Front Immunol. 2024 Oct 16:15:1462796. https://hdl.handle.net/20.500.12105/25566 39478867 10.3389/fimmu.2024.1462796 1664-3224 Frontiers in immunology CAR T LIN28 Immunotherapy Let-7 Osteosarcoma LIN28 upregulation in primary human T cells impaired CAR T antitumoral activity